ArticleFrontiers in immunology2025
Influenza-specific antibody-mediated and complement-dependent cellular cytotoxicity-inducing antibodies in vaccinated and infected pigs.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to neutralizing activity, antibodies can contribute to protection against viral infections through antibody-dependent cellular cytotoxicity (ADCC) and antibody-mediated complement-dependent cell cytotoxicity (CDC) mediated via Fcy receptors. Swine is a suitable large-animal biomedical model for influenza research, because it is a natural host for influenza like humans exhibiting comparable clinical and immunological responses. Unfortunately, there are currently limited insights into ADCC and CDC functions to swine influenza A virus (SwIAV) in pigs due to lack of adequate immunological tools. Therefore, the present study was aimed at optimizing the ADCC and CDC assays to evaluate the cytotoxicity mediated by virus-specific antibodies in response to vaccination of pigs with chitosan nanoparticle-based inactivated monovalent and commercial multivalent SwIAV vaccines administered through intranasal and intramuscular route, respectively. Using these assays, we quantified and compared the antibody-mediated cytotoxicity induced in pigs by intranasal chitosan nanoparticle-based inactivated monovalent whole SwIAV vaccine and intramuscular administered commercial multivalent SwIAV vaccine. Our results revealed that maternal antibody-positive pigs following vaccination with whole inactivated virus failed to elicit specific ADCC-mediating antibodies, but production of CDC antibodies was not affected. However, after exposure of vaccinated animals to challenge infection, high levels of ADCC antibodies were elicited. Further, it was observed that the function of virus-specific neutralizing and non-neutralizing antibodies are influenced by route of vaccination (intranasal versus intramuscular), vaccine type (monovalent versus multivalent) and adjuvant formulation. Overall, we observed a positive trend among the magnitude of ADCC, CDC, antibody avidity, Nabs, and HA inhibition (HAI) antibody responses in vaccinated and influenza virus-infected pigs. In conclusion, measuring ADCC- and CDC-mediating antibodies in pigs is important for evaluating the protective immunity against influenza by vaccines. Monitoring the function of both virus-neutralizing and non-neutralizing antibodies in vaccinated animals aid in the development of innovative cross-protective vaccine formulations to fight against constantly evolving influenza viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.